UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2006

NITROMED, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-50439	22-3159793
(State or Other Jurisdiction of	(Commission File Number)	(IRS Employer Identification No.)
Incorporation)

125 Spring Street
Lexington, Massachusetts		02421
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 266-4000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On October 11, 2006, NitroMed, Inc. (the “Company”) issued a press release announcing a revision of the Company’s strategy and business model, including the elimination and replacement of the Company’s current sales force with a small team of highly experienced senior cardiovascular specialists, resulting in a reduction of approximately 120 in sales force headcount. The Company also announced that it intends to focus its resources on the accelerated development of an extended release formulation of the Company’s product, BiDil® (isosorbide dinitrate/hydralazine hydrochloride), known as BiDil XR™. The full text of the Company’s press release regarding the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

	Exhibit No.		Description
	99.1		Press Release issued by NitroMed, Inc. on October 11, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	NITROMED, INC.

Date: October 11, 2006	By:	/s/ KENNETH M. BATE

		Kenneth M. Bate
		Chief Operating Officer, Chief Financial
		Officer, Treasurer and Secretary

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release issued by NitroMed, Inc. on October 11, 2006.